<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Peroxisome proliferator-activated receptor (PPAR) is involved in the pathology of numerous diseases including <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:mp ids='MP_0002055'>diabetes</z:mp>, and <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo>, because of its role in decreasing <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and <z:hpo ids='HP_0001513'>obesity</z:hpo> are the most frequent <z:chebi fb="32" ids="24621">endocrine</z:chebi>-<z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic diseases</z:e> and their pathogenic basis are characterized by <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and insulin secretion defects that can be demonstrated through several alterations in carbohydrates, <z:chebi fb="23" ids="18059">lipids</z:chebi>, and protein metabolism </plain></SENT>
<SENT sid="2" pm="."><plain>For that reason a class of compounds, called <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, has been developed for the management of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> are PPAR-γ <z:chebi fb="4" ids="48705">agonists</z:chebi> regulating the expression of several genes involved in the regulation of <z:chebi fb="105" ids="17234">glucose</z:chebi>, <z:chebi fb="23" ids="18059">lipid</z:chebi> and protein metabolism, enhancing the action of insulin in insulin-sensitive tissue by increasing <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in skeletal muscle and adipose tissue, and decreasing hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> production </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> is the only available PPAR-γ <z:chebi fb="4" ids="48705">agonist</z:chebi> for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> after <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> withdrawal from several countries </plain></SENT>
<SENT sid="5" pm="."><plain>This review discusses the safety and effectiveness of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> in the clinical practice for the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
</text></document>